scPharmaceuticals - SCPH Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCPH shares.
View SCPH analyst ratings or view top-rated stocks.

6 brokers have issued 1-year price objectives for scPharmaceuticals' stock. Their SCPH share price forecasts range from $12.00 to $25.00. On average, they anticipate the company's share price to reach $17.83 in the next twelve months. This suggests a possible upside of 150.5% from the stock's current price.
View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts.

scPharmaceuticals' stock was trading at $5.02 on January 1st, 2022. Since then, SCPH shares have increased by 41.8% and is now trading at $7.12.
View the best growth stocks for 2022 here.

scPharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 597,100 shares, an increase of 23.9% from the October 31st total of 482,000 shares. Based on an average daily volume of 405,300 shares, the short-interest ratio is presently 1.5 days. Currently, 3.4% of the shares of the stock are sold short.
View scPharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our SCPH earnings forecast.

scPharmaceuticals Inc. (NASDAQ:SCPH) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.41) by $0.04.

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

scPharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.08%), Worth Venture Partners LLC (0.69%), Renaissance Technologies LLC (0.66%), Dimensional Fund Advisors LP (0.51%), Belvedere Trading LLC (0.44%) and Boothbay Fund Management LLC (0.15%). Insiders that own company stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar, John H Tucker, Orbimed Advisors Llc and Ra Capital Management, LP.
View institutional ownership trends.

Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SCPH stock can currently be purchased for approximately $7.12.

scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $195.33 million. The company earns $-28,030,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com.